MME MARIE-PIERRE REVEL-DUBOIS

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Plateau technique de référence

Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes

Auteur de référence en rhumatologie

40 articles scientifiques publiés — un praticien à la pointe de la recherche

Délais de RDV courts dans la région

336.2 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 PARIS CEDEX 14 (75)HospitalierRPPS 10000603869

✨ Profil synthétique

IA · 24/05/2026

MME MARIE-PIERRE REVEL-DUBOIS est une rhumatologue hospitalière à Paris, spécialisée dans le traitement de diverses pathologies rhumatologiques. Ses publications sur PubMed révèlent une expertise dans les domaines de l'arthrite juvénile, des vascularites des gros vaisseaux et de l'économie de la santé. Elle a également participé à des essais cliniques et a publié des travaux sur la génétique et les csDMARDs.

Expertises présumées

Arthrite juvénile
Vascularites des gros vaisseaux
Essais cliniques
Génétique des maladies rhumatologiques
Traitement par csDMARDs
Économie de la santé en rhumatologie
Rhumatologie pédiatrique

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

GHU APHP CUP SITE COCHIN PORT ROYAL
27 R DU FAUBOURG SAINT JACQUES, 75679 PARIS CEDEX 14
☎ 0158414141Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Osteoblastic heparan sulfate glycosaminoglycans control bone remodeling by regulating Wnt signaling and the crosstalk between bone surface and marrow cells

Cell death & disease · 2017

📚 36 citations🎯 RCR 1.70🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

AbstractStimulating bone formation is an important challenge for bone anabolism in osteoporotic patients or to repair bone defects. The osteogenic properties of matrix glycosaminoglycans (GAGs) have been explored; however, the functions of GAGs at the surface of bone-forming cells are less documented. Syndecan-2 is a membrane heparan sulfate proteoglycan that is associated with osteoblastic differentiation. We used a transgenic mouse model with high syndecan-2 expression in osteoblasts to enrich the bone surface with cellular GAGs. Bone mass was increased in these transgenic mice. Syndecan-2 overexpression reduced the expression of receptor activator of NF-kB ligand (RANKL) in bone marrow cells and strongly inhibited bone resorption. Osteoblast activity was not modified in the transgenic mice, but bone formation was decreased in 4-month-old transgenic mice because of reduced osteoblast number. Increased proteoglycan expression at the bone surface resulted in decreased osteoblastic and osteoclastic precursors in bone marrow. Indeed, syndecan-2 overexpression increased apoptosis of mesenchymal precursors within the bone marrow. However, syndecan-2 specifically promoted the vasculature characterized by high expression of CD31 and Endomucin in 6-week-old transgenic mice, but this was reduced in 12-week-old transgenic mice. Finally, syndecan-2 functions as an inhibitor of Wnt-β-catenin–T-cell factor signaling pathway, activating glycogen synthase kinase 3 and then decreasing the Wnt-dependent production of Wnt ligands and R-spondin. In conclusion, our results show that GAG supply may improve osteogenesis, but also interfere with the crosstalk between the bone surface and marrow cells, altering the supporting function of osteoblasts.

Abstracts from the 3rd International Genomic Medicine Conference (3rd IGMC 2015) : Jeddah, Kingdom of Saudi Arabia. 30 November - 3 December 2015

BMC genomics · 2016

📚 25 citations🔓 Open Access📄 PDF gratuit ↗

Phase IV postmarketing surveillance study shows continued efficacy and safety of Stempeucel in patients with critical limb ischemia due to Buerger's disease

Stem cells translational medicine · 2021

📚 17 citations🎯 RCR 1.35🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Buerger's disease or thromboangiitis obliterans is a type of obstructive vascular diseases categorized as vasculitis and usually present in 95% of young smoker men. The main pathogenetic mechanism is interplay between immune system and inflammation. Earlier our phase II study has shown that Stempeucel is safe when injected at 2 million cells/kg body weight by virtue of its anti-inflammatory, immunomodulatory, and angiogenetic properties. The present study was conducted to further assess the safety and efficacy of Stempeucel in critical limb ischemia due to Buerger's disease after obtaining approval from Indian FDA based on the data generated in the phase II study. This is an open label, multicenteric phase IV PMS study conducted across India with experienced vascular surgeons. Fifty patients of critical limb ischemia due to Buerger's disease with Rutherford III-5 or III-6 were included in the study and each individual received a dose of 2 million cells/kg body weight of Stempeucel in the calf muscles and around the ulcer. These patients were evaluated over 12 months from drug administration. The present study showed the continued long term efficacy over a period of 12 months follow up in these patients corroborating the result obtained in the previous phase II studies. There was significant improvement in rest pain, ankle systolic pressure, and ankle brachial pressure index with accelerated ulcer healing. In conclusion, the present study shows that the intramuscular administration of Stempeucel continues to be safe, tolerable, and effective alternative treatment in patients with Buerger's disease.

Cookies & analyse de trafic

MME MARIE-PIERRE REVEL-DUBOIS

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (40) — classées par pathologie

Transversal17

Arthrite juvénile2

Essai clinique2

Génétique2

Vascularites des gros vaisseaux2

csDMARDs1

Économie santé1

Épidémiologie & registres1

IRM ostéo-articulaire1

JAK inhibiteurs1

Lombalgie1

Lupus1

Maladie à IgG41

Pharmacovigilance1

Qualité de vie / PROMs1

Revue générale1

SAPL1

Sjögren1

Tendinopathies & SCC1

Vascularites1

Vraie vie / RWE1

Partager cette fiche